Bronchitis - A Pipeline Analysis Report

Overview of the drug development pipeline for bronchitis

Bronchitis is a condition in which bronchial tubes become narrow and start secreting thick, pale, and discolored mucus. Bronchitis can either be acute or chronic. Bronchitis is usually caused by the virus, typically the same virus that causes cold and influenza. Patients suffering from bronchitis experience discomforts such as shortness of breath, chest discomfort, fatigue, cough, and slight fever and chills. Based on the bronchitis market forecast, Technavio’s market research analysts have predicted that with the introduction of yearly vaccination and adoption of the surgical mask as some of the most promising approaches to treat bronchitis, the global bronchitis market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II development stage. For instance, sponsors such as EmeraMed developed Emeramide, which is under phase II stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the discovery, phase III, phase II/III, and NDA development stages.

Bronchitis market forecast: Companies covered

Based on the bronchitis market growth analysis, this pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of bronchitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• EmeraMed
• Hunter Immunology
• Toyama Chemical

Therapeutic assessment of the drug development pipeline for bronchitis by the preferred route of administration

• Oral
• Subcutaneous

The intramuscular route of administration (ROA) involves the administration of drug substances directly into the muscle. It has been observed that the majority of total therapeutics are being developed for intramuscular administration.

Therapeutic assessment of the drug development pipeline for bronchitis by therapeutic modalities

• Small molecule
• Monoclonal antibody
• Vaccine

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for cervical dysplasia are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for bronchitis?
• What are the companies that are currently involved in the development of drug development molecules for bronchitis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.